AR035411A1 - Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto - Google Patents

Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto

Info

Publication number
AR035411A1
AR035411A1 ARP010106058A ARP010106058A AR035411A1 AR 035411 A1 AR035411 A1 AR 035411A1 AR P010106058 A ARP010106058 A AR P010106058A AR P010106058 A ARP010106058 A AR P010106058A AR 035411 A1 AR035411 A1 AR 035411A1
Authority
AR
Argentina
Prior art keywords
agent
manufacturing
manufacture
derivative
graints
Prior art date
Application number
ARP010106058A
Other languages
English (en)
Spanish (es)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR035411A1 publication Critical patent/AR035411A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
ARP010106058A 2000-12-29 2001-12-27 Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto AR035411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29

Publications (1)

Publication Number Publication Date
AR035411A1 true AR035411A1 (es) 2004-05-26

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106058A AR035411A1 (es) 2000-12-29 2001-12-27 Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto

Country Status (18)

Country Link
EP (1) EP1353671A4 (fr)
JP (1) JP2004527472A (fr)
KR (2) KR100794204B1 (fr)
CN (1) CN1293877C (fr)
AR (1) AR035411A1 (fr)
AU (1) AU2002231277B2 (fr)
BR (1) BR0116762A (fr)
CA (1) CA2433384A1 (fr)
CZ (1) CZ20032060A3 (fr)
HU (1) HUP0302521A3 (fr)
IL (1) IL156664A0 (fr)
MX (1) MXPA03005941A (fr)
NO (1) NO20032913D0 (fr)
NZ (1) NZ527209A (fr)
PL (1) PL366301A1 (fr)
RU (1) RU2288716C2 (fr)
WO (1) WO2002053159A1 (fr)
ZA (1) ZA200305806B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
JP2007518692A (ja) * 2004-01-20 2007-07-12 アステラス製薬株式会社 勃起不全治療方法
EP1810675A1 (fr) * 2006-01-18 2007-07-25 Institut Curie Methode de traitement de la maladie de Huntington par l'inhibition de la dephosphorylation de la S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
CA2730751A1 (fr) * 2008-07-23 2010-01-28 Novartis Ag Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire
EP2817009A1 (fr) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Inhibiteurs de la calcineurine destinés à être utilisés dans le traitement des troubles vestibulaires entraînant des lésions
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
EP1353671A1 (fr) 2003-10-22
KR100794204B1 (ko) 2008-01-14
CA2433384A1 (fr) 2002-07-11
NO20032913D0 (no) 2003-06-24
HUP0302521A3 (en) 2007-03-28
AU2002231277B2 (en) 2006-11-30
KR20070030331A (ko) 2007-03-15
CN1538843A (zh) 2004-10-20
JP2004527472A (ja) 2004-09-09
ZA200305806B (en) 2005-01-26
EP1353671A4 (fr) 2004-07-14
NZ527209A (en) 2005-09-30
CN1293877C (zh) 2007-01-10
RU2288716C2 (ru) 2006-12-10
HUP0302521A2 (hu) 2003-11-28
RU2003123493A (ru) 2005-01-20
MXPA03005941A (es) 2005-02-14
CZ20032060A3 (cs) 2004-01-14
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04
PL366301A1 (en) 2005-01-24
WO2002053159A1 (fr) 2002-07-11
BR0116762A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
DE60112897D1 (de) Stabilisierung von implantierbarem bioprothesegewebe
MY148952A (en) Ethylene/(?)-olefins compositions, articles made therefrom and methods for preparing the same
ATE382681T1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
BR0116345A (pt) Composiçõs de contra-ação ao mau cheiro
MX2007003093A (es) Composiciones de tratamientos de lavanderia.
AR005439A1 (es) Composicion desinfectante, pano que la contiene y proceso para desinfectar una superficie con dicha composicion
AR018240A1 (es) Composiciones de tinte de fibras queratinicas que contienen derivados de pirazolo-[1,5-a]-pirimidina, procedimiento de tinte, nuevos derivados depirazolo-[1,5-a]-pirimidina y su procedimiento de preparacion
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
SE9703289L (sv) Stabilisatorkomposition
MX9308043A (es) Composicion blanqueadora espesada, con olor a blanqueador reducido y metodo para su fabricacion y uso.
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
ECSP045146A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
MXPA05011512A (es) Composiciones sellantes antimicrobianas, desinfectantes y metodos para usar las mismas.
EP1208129A1 (fr) Compositions de polyurethanne derivees et leurs procedes de fabrication
BR0000654A (pt) Preparação de composição de borracha vulcanizada com peróxido e artigos tendo ela pelo menos como um dos seus componentes
AR035411A1 (es) Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
ES2195149T3 (es) Densificacion de una estructura porosa (ii).
HUP0100974A2 (hu) Integrált additív készítmény, eljárás előállítására és alkalmazására
ES2155664T3 (es) Colorantes reactivos, obtencion y uso de los mismos.
CA2433596A1 (fr) Compositions pour le traitement de chaussures et procedes et articles utilisant ces compositions
ES2054933T3 (es) Ciclopropanocarboxamidas, procedimiento para su obtencion y su empleo para la lucha contra las pestes.
ES2126304T3 (es) Soporte para el cultivo de los champiñones, que favorece el crecimiento del micelio y el desarrollo de los carpoforos, asi como su procedimiento de obtencion.
FI913933A (fi) Genomgaoende taeck- och taetningsmedel baserade pao polyuretandispersioner.

Legal Events

Date Code Title Description
FB Suspension of granting procedure